UNSPSC 51171982: Ranitidine bismuth citrate

This classification denotes a histamine-2 receptor antagonist with the molecular formula C13H22N4O3S.C6H5O7.Bi, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7AJ51I17KG, chemically known as 1,2,3-propanetricarboxylic acid, 2-hydroxy-, bismuth(3(+)) salt (1:1), compd. with n-(2-(((5-((dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-n-methyl-2-nitro-1,1-ethenediamine (1:1) but more generally known as ranitidine bismuth citrate, which bears US NIH Compound Identifier 3033887.

UNSPSC 51171982 Ranitidine bismuth citrate is a Commodity code that captures state and local procurement of specific pharmaceutical active ingredients and finished drug products, though recent solicitation activity under this code shows minimal direct relevance. The recent opportunities posted under this code span drug testing services, direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals — none of which involve ranitidine bismuth citrate as a primary procurement target. State and local issuing bodies pursuing pharmaceutical purchases include county community supervision and corrections departments (seeking drug-testing laboratory services), state health and human services commissions (seeking pharmacy benefit management solutions), and multistate cooperative purchasing alliances (seeking generic pharmaceutical and OTC product distribution contracts). The fragmented issuing-body mix reflects the broad range of state, county, and cooperative entities managing pharmaceutical procurement across correctional, public-health, and employee-benefit contexts.

Geographic activity centers on Texas and Minnesota, with the most concrete recent opportunity originating from Collin County Community Supervision and Corrections Department (RFP 2026-327 for offender specimen collection and drug testing services, due July 23, 2026, estimated value $600,000 over two years). Texas Health and Human Services Commission posted an RFI on April 3, 2026 regarding direct-to-manufacturer prescription programs, while the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP on January 20, 2026 for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline. The disconnect between the code's nominal product (ranitidine bismuth citrate, a gastric ulcer treatment) and the actual scope of recent solicitations — testing services, pharmacy benefit management, and generic pharmaceutical distribution — suggests the code carries minimal relevant activity for vendors supplying this specific active ingredient to state and local buyers.